Drug Claim Symptoms Spread Among Supplement Marketers Targeting Ebola Fears
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest FDA/FTC joint warning letters advise Life Silver, Bodyhealth.com LLC and Ebola-C Inc. that their online claims render their products unapproved new drugs. FDA directs the firms to respond to an “EbolaTaskForce-CFSAN” email address rather than to an ORA address typical of most warning letters.
You may also be interested in...
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola. One firm’s website offers a video titled, “Urgent Message to Ebola-Stricken Nations' Heads of State,” and another claims “primary uses for oregano include athlete’s foot, candida, canker sores, Ebola virus.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.